60 related articles for article (PubMed ID: 9758674)
1. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
[TBL] [Abstract][Full Text] [Related]
2. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
Sham HL; Kempf DJ; Molla A; Marsh KC; Kumar GN; Chen CM; Kati W; Stewart K; Lal R; Hsu A; Betebenner D; Korneyeva M; Vasavanonda S; McDonald E; Saldivar A; Wideburg N; Chen X; Niu P; Park C; Jayanti V; Grabowski B; Granneman GR; Sun E; Japour AJ; Leonard JM; Plattner JJ; Norbeck DW
Antimicrob Agents Chemother; 1998 Dec; 42(12):3218-24. PubMed ID: 9835517
[TBL] [Abstract][Full Text] [Related]
3. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir.
Sevrioukova IF; Poulos TL
Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18422-7. PubMed ID: 20937904
[TBL] [Abstract][Full Text] [Related]
4. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.
Wang A; Stout CD; Zhang Q; Johnson EF
J Biol Chem; 2015 Feb; 290(8):5092-5104. PubMed ID: 25555909
[TBL] [Abstract][Full Text] [Related]
5.
Shimizu M; Uehara S; Ohyama K; Nishimura H; Tanaka Y; Saito Y; Suemizu H; Yoshida S; Yamazaki H
Drug Metab Dispos; 2023 Oct; ():. PubMed ID: 37879849
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy.
von Hentig N
HIV AIDS (Auckl); 2016; 8():1-16. PubMed ID: 26730211
[TBL] [Abstract][Full Text] [Related]
7. The effect of ritonavir on the pharmacokinetics of clonidine in vivo and in vitro.
Wang P; Hu X
Pak J Pharm Sci; 2023 Nov; 36(6):1729-1734. PubMed ID: 38124412
[TBL] [Abstract][Full Text] [Related]
8. Stimulatory and inhibitory effect of antipsychotic agents including dopaminergic neuro-depressants on dopamine formation from p-tyramine mediated by cytochrome P450 2D6.
Niwa T; Yamamoto Y
Drug Metab Bioanal Lett; 2023 Sep; ():. PubMed ID: 37711131
[TBL] [Abstract][Full Text] [Related]
9. Drug interactions due to cytochrome P450.
Ogu CC; Maxa JL
Proc (Bayl Univ Med Cent); 2000 Oct; 13(4):421-3. PubMed ID: 16389357
[TBL] [Abstract][Full Text] [Related]
10. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT).
Lemaitre F; Grégoire M; Monchaud C; Bouchet S; Saint-Salvi B; Polard E; ; ; ; ; ;
Therapie; 2022; 77(5):509-521. PubMed ID: 35618549
[TBL] [Abstract][Full Text] [Related]
11. Quinidine in the treatment of KCNT1-positive epilepsies.
Mikati MA; Jiang YH; Carboni M; Shashi V; Petrovski S; Spillmann R; Milligan CJ; Li M; Grefe A; McConkie A; Berkovic S; Scheffer I; Mullen S; Bonner M; Petrou S; Goldstein D
Ann Neurol; 2015 Dec; 78(6):995-9. PubMed ID: 26369628
[TBL] [Abstract][Full Text] [Related]
12. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.
Greenblatt DJ; Harmatz JS
Br J Clin Pharmacol; 2015 Sep; 80(3):342-50. PubMed ID: 25923589
[TBL] [Abstract][Full Text] [Related]
13. Physiology-based IVIVE predictions of tramadol from in vitro metabolism data.
T'jollyn H; Snoeys J; Colin P; Van Bocxlaer J; Annaert P; Cuyckens F; Vermeulen A; Van Peer A; Allegaert K; Mannens G; Boussery K
Pharm Res; 2015 Jan; 32(1):260-74. PubMed ID: 25048637
[TBL] [Abstract][Full Text] [Related]
14. Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.
Grün B; Merkel U; Riedel KD; Weiss J; Mikus G
Br J Clin Pharmacol; 2012 Nov; 74(5):854-63. PubMed ID: 22381043
[TBL] [Abstract][Full Text] [Related]
15. Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.
Kirby BJ; Collier AC; Kharasch ED; Dixit V; Desai P; Whittington D; Thummel KE; Unadkat JD
Drug Metab Dispos; 2011 Dec; 39(12):2329-37. PubMed ID: 21930825
[TBL] [Abstract][Full Text] [Related]
16. Safety considerations in drug treatment of depression in HIV-positive patients: an updated review.
Watkins CC; Pieper AA; Treisman GJ
Drug Saf; 2011 Aug; 34(8):623-39. PubMed ID: 21751824
[TBL] [Abstract][Full Text] [Related]
17. Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
Rudek MA; Flexner C; Ambinder RF
Lancet Oncol; 2011 Sep; 12(9):905-12. PubMed ID: 21570912
[TBL] [Abstract][Full Text] [Related]
18. Coprescription of tamoxifen and medications that inhibit CYP2D6.
Sideras K; Ingle JN; Ames MM; Loprinzi CL; Mrazek DP; Black JL; Weinshilboum RM; Hawse JR; Spelsberg TC; Goetz MP
J Clin Oncol; 2010 Jun; 28(16):2768-76. PubMed ID: 20439629
[TBL] [Abstract][Full Text] [Related]
19. Choosing Antidepressants for HIV and AIDS Patients: Insights on Safety and Side Effects.
Yanofski J; Croarkin P
Psychiatry (Edgmont); 2008 May; 5(5):61-6. PubMed ID: 19727253
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
